Trusted byOracleSnowflakeCloudflareLinkedInGoogleSalesforce★★★★★4.8/5 on G2
LaunchLumiThera Inc. announces FDA authorization of Valeda Light Delivery System to improve vision in dry AMD patients.
Nov 05, 2024
PoulsboInformation TechnologyHealthcareHealth Care
Product Description
LumiThera Inc. has received FDA authorization for its Valeda Light Delivery System, the first-ever treatment for vision loss in patients with dry age-related macular degeneration (AMD). The device aims to improve best corrected visual acuity over 24 months, marking a significant advancement in non-invasive treatment options for disease progression.
Company Information
Company
LumiThera
Location
19578 10TH AVE NE, SUITE 200
Poulsbo, Washington, United States
About
LumiThera, Inc. is a commercial-stage medical device company initially focused on treating patients affected by dry age-related macular degeneration. The Company’s expertise is in the application of photobiomodulation (“PBM”), using non-invasive light emitting diodes (“LED”) for acute and chronic ocular diseases and disorders. The Company is developing an ophthalmic LED office-based instrument to be used in multiple ocular conditions or disorders as non-invasive medical treatments.
AI made execution free. Knowing first is the whole game now.
Fundz sees it the moment LumiThera ships something new, hires an exec or expands, usually minutes after it happens, and tells you who to reach.